Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Schizophrenia

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Schizophrenia

8 stories · every one Fact-Checked
Obuprazine Phase 2b trial results showing PANSS score improvements in adults with schizophreniaClinical TrialsTortugas Reports Positive Phase 2b Results for Obuprazine in SchizophreniaTortugas Neuroscience reported that obuprazine met the Phase 2b primary endpoint in schizophrenia, with all three dose groups significantly improving PANSS scores versus placebo.13 Oct 2026 · 4 min read
Fact-Checked
Click Therapeutics Motivista digital therapeutic receives FDA 510(k) clearance for schizophrenia negative symptomsMedical DevicesClick’s Motivista Receives FDA Clearance for Negative Symptoms of SchizophreniaClick Therapeutics’ Motivista (CT-155) has received FDA 510(k) clearance as an adjunctive prescription digital therapeutic for negative symptoms of schizophrenia in adults with clinically stable positive symptoms.6 Oct 2026 · 4 min read
Fact-Checked
UZEDY risperidone long-acting injectable treatment for schizophrenia and bipolar I disorderClinical TrialsTeva’s UZEDY Shows Real-World Benefits in SchizophreniaTeva presented new real-world data for UZEDY (risperidone) showing greater treatment continuity and lower emergency care use in schizophrenia, alongside lower treatment failure after switching from oral antipsychotics…21 Sep 2026 · 3 min read
Fact-Checked
TEV-'749 once-monthly subcutaneous olanzapine LAI for adults with schizophreniaClinical TrialsTEV-‘749 Shows Durable Results in Phase 3 Schizophrenia TrialTeva’s investigational once-monthly subcutaneous olanzapine LAI TEV-‘749 showed durable stabilization and low relapse in a Phase 3 SOLARIS analysis, while switching analyses supported predictable olanzapine exposure after transition…21 Sep 2026 · 4 min read
Fact-Checked
Leal Therapeutics LTX-001 schizophrenia and LTX-002 ALS clinical developmentHealth TidingsEli Lilly Joins $30 Million Series A to Advance Leal’s Schizophrenia and ALS ProgramsLeal Therapeutics has secured $30 million in a second Series A financing to advance LTX-001 through a Phase 1b/2a trial in schizophrenia and expand LTX-002 development in ALS…18 Aug 2026 · 2 min read
Fact-Checked
Illustration of ML-007C-MA (betovumeline and fesoterodine) showing positive Phase 2 ZEPHYR trial results in adults with acute schizophrenia.Health TidingsMapLight Reports Positive Phase 2 Results for ML-007C-MA in SchizophreniaMapLight Therapeutics reported positive Phase 2 ZEPHYR results for ML-007C-MA, an investigational oral combination of betovumeline and fesoterodine, in adults with acute schizophrenia.27 Jul 2026 · 4 min read
Fact-Checked
Teva_Logo_RGBHealth TidingsEMA Accepts TEV-‘749 Application for Adults With SchizophreniaTeva and Medincell’s investigational long‑acting olanzapine, TEV‑‘749, has advanced after EMA accepted its Marketing Authorization Application.22 May 2026 · 3 min read
Fact-Checked
Boehringer Ingelheim's JASCAYD (nerandomilast), the first oral PDE4B inhibitor, receives European Commission approval for treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).Mergers & AcquisitionsBoehringer, Click Move CT-155 to Frontline in SchizophreniaClick Therapeutics will lead commercialization of CT-155 after Boehringer Ingelheim transfers full product responsibility and invests $50 million, supported by Phase III CONVOKE data showing improvement in schizophrenia…12 Apr 2026 · 3 min read
Fact-Checked
Page 1 of 1